Cargando…
T192. THE GUT MICROBIOME IN SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED METABOLIC DYSFUNCTION
BACKGROUND: Antipsychotic (AP) medications are the cornerstone of treatment for schizophrenia (SCZ), with off-label prescription rapidly increasing in youth and adolescent populations. However, APs have been associated with metabolic side effects including diabetes and obesity. Although several mech...
Autores principales: | Kanji, Sarah, Gorbovskaya, Ilona, Fonseka, Trehani, Yoshida, Kazunari, Marshe, Victoria, MacKenzie, Malgorzata, Bercik, Premysl, Verdu, Elena, Hahn, Margaret, Mueller, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888799/ http://dx.doi.org/10.1093/schbul/sby016.468 |
Ejemplares similares
-
The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment
por: Raben, Alex T., et al.
Publicado: (2018) -
The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment
por: Liu, Jonathan C. W., et al.
Publicado: (2021) -
M172. POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN
por: Yoshida, Kazunari, et al.
Publicado: (2020) -
Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018) -
Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
por: Singh, Raghunath, et al.
Publicado: (2022)